ErbB3-dependent motility and intravasation in breast cancer metastasis

Chengsen Xue, Fubo Liang, Radma Mahmood, Magalis Vuolo, Jeffrey Wyckoff, Hong Qian, Kun Lin Tsai, Mimi Kim, Joseph Locker, Zhong-Yin Zhang, Jeffrey E. Segall

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

A better understanding of how epidermal growth factor receptor family members (ErbBs) contribute to metastasis is important for evaluating ErbB-directed therapies. Activation of ErbB3/ErbB2 heterodimers can affect both proliferation and motility. We find that increasing ErbB3-dependent signaling in orthotopic injection models of breast cancer can enhance intravasation and lung metastasis with no effect on primary tumor growth or microvessel density. Enhanced metastatic ability due to increased expression of ErbB2 or ErbB3 correlated with stronger chemotaxis and invasion responses to heregulin β1. Suppression of ErbB3 expression reduced both intravasation and metastasis. A human breast cancer tumor tissue microarray showed a significant association between ErbB3 and ErbB2 expression and metastasis independent of tumor size. These results indicate that ErbB3-dependent signaling through ErbB3/ErbB2 heterodimers can contribute to metastasis through enhancing tumor cell invasion and intravasation in vivo and that ErbB-directed therapies may be useful for the inhibition of invasion independent of effects on tumor growth.

Original languageEnglish (US)
Pages (from-to)1418-1426
Number of pages9
JournalCancer Research
Volume66
Issue number3
DOIs
StatePublished - Feb 1 2006
Externally publishedYes

Fingerprint

Breast Neoplasms
Neoplasm Metastasis
Neoplasms
Neuregulin-1
Aptitude
Chemotaxis
Growth
Microvessels
Epidermal Growth Factor Receptor
Lung
Injections
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Xue, C., Liang, F., Mahmood, R., Vuolo, M., Wyckoff, J., Qian, H., ... Segall, J. E. (2006). ErbB3-dependent motility and intravasation in breast cancer metastasis. Cancer Research, 66(3), 1418-1426. https://doi.org/10.1158/0008-5472.CAN-05-0550

ErbB3-dependent motility and intravasation in breast cancer metastasis. / Xue, Chengsen; Liang, Fubo; Mahmood, Radma; Vuolo, Magalis; Wyckoff, Jeffrey; Qian, Hong; Tsai, Kun Lin; Kim, Mimi; Locker, Joseph; Zhang, Zhong-Yin; Segall, Jeffrey E.

In: Cancer Research, Vol. 66, No. 3, 01.02.2006, p. 1418-1426.

Research output: Contribution to journalArticle

Xue, C, Liang, F, Mahmood, R, Vuolo, M, Wyckoff, J, Qian, H, Tsai, KL, Kim, M, Locker, J, Zhang, Z-Y & Segall, JE 2006, 'ErbB3-dependent motility and intravasation in breast cancer metastasis', Cancer Research, vol. 66, no. 3, pp. 1418-1426. https://doi.org/10.1158/0008-5472.CAN-05-0550
Xue C, Liang F, Mahmood R, Vuolo M, Wyckoff J, Qian H et al. ErbB3-dependent motility and intravasation in breast cancer metastasis. Cancer Research. 2006 Feb 1;66(3):1418-1426. https://doi.org/10.1158/0008-5472.CAN-05-0550
Xue, Chengsen ; Liang, Fubo ; Mahmood, Radma ; Vuolo, Magalis ; Wyckoff, Jeffrey ; Qian, Hong ; Tsai, Kun Lin ; Kim, Mimi ; Locker, Joseph ; Zhang, Zhong-Yin ; Segall, Jeffrey E. / ErbB3-dependent motility and intravasation in breast cancer metastasis. In: Cancer Research. 2006 ; Vol. 66, No. 3. pp. 1418-1426.
@article{1c9506327c7d4e8ba19a6a9e2ff74172,
title = "ErbB3-dependent motility and intravasation in breast cancer metastasis",
abstract = "A better understanding of how epidermal growth factor receptor family members (ErbBs) contribute to metastasis is important for evaluating ErbB-directed therapies. Activation of ErbB3/ErbB2 heterodimers can affect both proliferation and motility. We find that increasing ErbB3-dependent signaling in orthotopic injection models of breast cancer can enhance intravasation and lung metastasis with no effect on primary tumor growth or microvessel density. Enhanced metastatic ability due to increased expression of ErbB2 or ErbB3 correlated with stronger chemotaxis and invasion responses to heregulin β1. Suppression of ErbB3 expression reduced both intravasation and metastasis. A human breast cancer tumor tissue microarray showed a significant association between ErbB3 and ErbB2 expression and metastasis independent of tumor size. These results indicate that ErbB3-dependent signaling through ErbB3/ErbB2 heterodimers can contribute to metastasis through enhancing tumor cell invasion and intravasation in vivo and that ErbB-directed therapies may be useful for the inhibition of invasion independent of effects on tumor growth.",
author = "Chengsen Xue and Fubo Liang and Radma Mahmood and Magalis Vuolo and Jeffrey Wyckoff and Hong Qian and Tsai, {Kun Lin} and Mimi Kim and Joseph Locker and Zhong-Yin Zhang and Segall, {Jeffrey E.}",
year = "2006",
month = "2",
day = "1",
doi = "10.1158/0008-5472.CAN-05-0550",
language = "English (US)",
volume = "66",
pages = "1418--1426",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - ErbB3-dependent motility and intravasation in breast cancer metastasis

AU - Xue, Chengsen

AU - Liang, Fubo

AU - Mahmood, Radma

AU - Vuolo, Magalis

AU - Wyckoff, Jeffrey

AU - Qian, Hong

AU - Tsai, Kun Lin

AU - Kim, Mimi

AU - Locker, Joseph

AU - Zhang, Zhong-Yin

AU - Segall, Jeffrey E.

PY - 2006/2/1

Y1 - 2006/2/1

N2 - A better understanding of how epidermal growth factor receptor family members (ErbBs) contribute to metastasis is important for evaluating ErbB-directed therapies. Activation of ErbB3/ErbB2 heterodimers can affect both proliferation and motility. We find that increasing ErbB3-dependent signaling in orthotopic injection models of breast cancer can enhance intravasation and lung metastasis with no effect on primary tumor growth or microvessel density. Enhanced metastatic ability due to increased expression of ErbB2 or ErbB3 correlated with stronger chemotaxis and invasion responses to heregulin β1. Suppression of ErbB3 expression reduced both intravasation and metastasis. A human breast cancer tumor tissue microarray showed a significant association between ErbB3 and ErbB2 expression and metastasis independent of tumor size. These results indicate that ErbB3-dependent signaling through ErbB3/ErbB2 heterodimers can contribute to metastasis through enhancing tumor cell invasion and intravasation in vivo and that ErbB-directed therapies may be useful for the inhibition of invasion independent of effects on tumor growth.

AB - A better understanding of how epidermal growth factor receptor family members (ErbBs) contribute to metastasis is important for evaluating ErbB-directed therapies. Activation of ErbB3/ErbB2 heterodimers can affect both proliferation and motility. We find that increasing ErbB3-dependent signaling in orthotopic injection models of breast cancer can enhance intravasation and lung metastasis with no effect on primary tumor growth or microvessel density. Enhanced metastatic ability due to increased expression of ErbB2 or ErbB3 correlated with stronger chemotaxis and invasion responses to heregulin β1. Suppression of ErbB3 expression reduced both intravasation and metastasis. A human breast cancer tumor tissue microarray showed a significant association between ErbB3 and ErbB2 expression and metastasis independent of tumor size. These results indicate that ErbB3-dependent signaling through ErbB3/ErbB2 heterodimers can contribute to metastasis through enhancing tumor cell invasion and intravasation in vivo and that ErbB-directed therapies may be useful for the inhibition of invasion independent of effects on tumor growth.

UR - http://www.scopus.com/inward/record.url?scp=32944465535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32944465535&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-05-0550

DO - 10.1158/0008-5472.CAN-05-0550

M3 - Article

C2 - 16452197

AN - SCOPUS:32944465535

VL - 66

SP - 1418

EP - 1426

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 3

ER -